

Supplement Documents for Results FY2010

Astellas Pharma Inc.

- Financial Results of FY2010
- Pipeline list

Cautionary statement regarding forward-looking information

This material includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, the pricing and product initiatives of competitors, the inability of the company to market existing and new product effectively, interruptions in production, infringement of the company's intellectual property rights and the adverse outcome of material litigation.

1.Consolidated Results

rounddown under 0.1 billion yen

billion yen

	Mar 10 Full Year	Mar 11 Full Year	Change	Change (%)
Net Sales	974.8	953.9	-20.9	-2.1%
Cost of Sales	289.2	295.9	6.7	2.3%
Ratio to Net Sales	29.7%	31.0%		
Gross Profit	685.6	657.9	-27.6	-4.0%
SG&A	499.2	538.7	39.5	7.9%
Ratio to Net Sales	51.2%	56.5%		
Research and Development	195.5	217.3	21.7	11.1%
SG&A excluding R&D	303.6	321.4	17.8	5.9%
Advertising and Sales Promotion	87.7	88.9	1.2	1.4%
Salaries, Bonuses and Allowances	120.0	120.7	0.7	0.6%
Other	95.8	111.6	15.8	16.5%
Operating Income	186.4	119.1	-67.2	-36.1%
Ratio to Net Sales	19.1%	12.5%		
Non-Operating Income	5.1	3.1	-1.9	-38.3%
Non-Operating Expenses	0.5	7.3	6.7	1140.5%
Exchange Loss	-	6.5	6.5	-
Ordinary Income	190.9	115.0	-75.9	-39.8%
Ratio to Net Sales	19.6%	12.1%		
Special Gains	3.0	1.6	-1.3	-44.6%
Gain on sales of investment securities	2.7	1.2	-1.4	-52.6%
Special Losses	7.2	13.2	6.0	83.8%
Loss on sale and disposal of fixed assets	2.2	1.2	-1.0	-44.1%
Loss on impairment of fixed assets	4.0	2.7	-1.2	-31.8%
Loss on disaster	-	3.0	3.0	-
Business integration expenses	-	4.7	4.7	-
Other	0.8	1.4	0.5	70.2%
Income before Income Taxes	186.8	103.4	-83.3	-44.6%
Income Taxes	62.6	35.8	-26.7	-42.8%
Minority Interests	1.9	-	-1.9	-
Net Income	122.2	67.6	-54.6	-44.7%
Ratio to Net Sales	12.5%	7.1%		
Comprehensive income	108.6	24.9	-83.7	-77.1%

Mar 11 Revised
942.0
206.0
124.0
13.2%
122.0
13.0%
82.0
8.7%

Forecasts

Forecasts

Mar 12 2Q	Change (%)	Mar 12 Full Year	Change (%)
478.0	3.5%	974.0	2.1%
98.0	-6.5%	199.0	-8.4%
71.0	4.5%	135.0	13.3%
14.9%		13.9%	
72.0	9.9%	136.5	18.6%
15.1%		14.0%	
39.0	-11.1%	81.0	19.7%
8.2%		8.3%	

2. Segment Information by Region

billion yen

	Mar 10 Full Year	Mar 11 Full Year	Change	Change (%)
Net Sales	974.8	953.9	-20.9	-2.1%
Japan	529.2	543.8	14.5	2.8%
Ratio to Net Sales	54.3%	57.0%		
Americas	179.8	186.5	6.7	3.7%
Ratio to Net Sales	18.4%	19.6%		
Europe	235.8	189.8	-45.9	-19.5%
Ratio to Net Sales	24.2%	19.9%		
Asia	29.9	33.7	3.7	12.5%
Ratio to Net Sales	3.1%	3.5%		
Operating Income	186.4	119.1	-67.2	-36.1%
Japan	114.5	68.5	-45.9	-40.2%
Ratio to Net Sales	61.4%	57.5%		
Americas	14.8	9.1	-5.6	-38.5%
Ratio to Net Sales	7.9%	7.7%		
Europe	43.9	36.2	-7.6	-17.5%
Ratio to Net Sales	23.6%	30.4%		
Asia	2.3	2.0	-0.2	-13.0%
Ratio to Net Sales	1.2%	1.7%		
Eliminations	10.8	3.2	-7.5	

- Calculated according to locations of sellers.

3. Overseas Sales

billion yen

	Mar 10 Full Year	Mar 11 Full Year	Change	Change (%)
Overseas Sales	460.7	422.5	-38.1	-8.3%
Americas	224.8	189.4	-35.3	-15.7%
Ratio to Net Sales	47.3%	44.3%		
Europe	181.2	181.9	0.7	0.4%
Ratio to Net Sales	23.1%	19.9%		
Asia and others	54.5	51.0	-3.5	-6.4%
Ratio to Net Sales	18.6%	19.1%		
Ratio to Net Sales	5.6%	5.4%		

- Calculated according to locations of buyers.

Mar 11 Revised
942.0
535.6
56.9%
189.4
20.1%
183.4
19.5%
33.6
3.6%
124.0

Forecasts

Forecasts

Mar 12 2Q	Change (%)	Mar 12 Full Year	Change (%)
478.0	3.5%	974.0	2.1%
268.5	2.8%	550.8	1.3%
56.2%		56.6%	
96.7	9.1%	192.7	3.3%
20.2%		19.8%	
93.6	-1.2%	191.3	0.8%
19.6%		19.6%	
19.2	11.5%	39.2	16.2%
4.0%		4.0%	
71.0	4.5%	135.0	13.3%

4.Exchange Rate

	yen			
	Mar 10 Ave	Mar 11 Ave	Mar 10 End	Mar 11 End
Yen/USD	93	86	93	83
Yen/EUR	131	113	125	118

Mar 11 Revised
84
112

Forecasts	
Mar 12 2Q	
80	
110	

Forecasts	
Mar 12 Full Year	
80	
110	

* Exchange rate fluctuations had negative impact by 47.3 billion yen on net sales and negative impact by 8.6 billion yen on operating income in FY10

5.Per Share Information

	Mar 10 Full Year	Mar 11 Full Year
The number of share issued (thousand)	475,964	467,964
Treasury Stock (thousand)	14,146	6,138
The number of share issued after deducting Treasury Stock (thousand)	461,817	461,826
Earnings per share (Yen)	261.84	146.49
Dividend per share (Yen)	125	125
Return on Equity (%)	11.7%	6.5%
Dividend on Earnings (%)	5.6%	5.6%

Mar 11 Revised
177.56
125

Forecasts	
Mar 12 2Q	
93.11	
60	

Forecasts	
Mar 12 Full Year	
175.39	
125	

6.Research and Development Expenses

	billion yen			
	Mar 10 Full Year	Mar 11 Full Year	Change	Change (%)
Research and Development	195.5	217.3	21.7	11.1%
Ratio to Net Sales	20.1%	22.8%		

billion yen	
Mar 11 Revised	
206.0	
21.9%	

Forecasts		Forecasts	
Mar 12 2Q	Change (%)	Mar 12 Full Year	Change (%)
98.0	-6.5%	199.0	-8.4%
20.1%		20.4%	

7.Addition to Property, Plant and Equipment

	billion yen			
	Mar 10 Full Year	Mar 11 Full Year	Change	Change (%)
Addition to Property, Plant and Equipment				
Consolidated	37.7	35.1	-2.6	-7.0%
Depreciation(Tangible)				
Consolidated	28.0	27.5	-0.4	-1.6%
Depreciation(Intangible)				
Consolidated	10.6	26.9	16.2	152.6%
Amortization of Goodwill	9.7	11.1		
Agensys	9.7	7.4		
OSI	-	3.5		

billion yen	
Mar 11 Revised	
43.0	
28.0	
27.4	
10.7	
7.3	
3.4	

Forecasts	
Mar 12 Full Year	Change (%)
44.0	25.2%
28.5	3.4%
32.0	18.9%
11.3	
6.9	
4.4	

8.Employee

Number of employees

	Mar 10 FY End	Mar 11 FY End
Total	15,161	*16,279
Japan	7,860	8,023
Americas	2,375	*2,742
Europe	3,775	*4,102
Asia	1,151	1,412
Total Medical Representatives	5,500	*5,800

* Including 423 employees of OSI (End of Mar 2011)

9.Shareholders

	Mar 10 FY End	Mar 11 FY End
Banks	33.7%	33.3%
Securities	4.2%	5.8%
Other companies	4.0%	4.1%
Foreign companies	46.3%	45.8%
Individuals and others	8.8%	9.5%
Treasury Stock	3.0%	1.3%

10.Detailed Pharmaceutical Segment Information

1)Consolidated sales of major products

	billion yen				Mar 11 Revised	Forecasts			
	Mar 10 Full Year	Mar 11 Full Year	Change	Change (%)		Mar 12 2Q	Change (%)	Mar 12 Full Year	Change (%)
Prograf	186.7	162.6	-24.1	-12.9%	154.7	78.5	-3.9%	155.5	-4.4%
Sales by Astellas	180.5	156.1	-24.4	-13.5%	148.7	75.8	-3.9%	150.4	-3.7%
Japan (Including Gracceptor)	33.8	39.6	5.8	17.3%	38.8	21.6	12.5%	44.5	12.2%
Americas	68.1	41.0	-27.1	-39.9%	39.3	17.8	-16.2%	34.3	-16.1%
Europe	65.7	60.6	-5.1	-7.8%	56.6	28.8	-6.2%	56.0	-7.6%
Advagraf	12.1	13.8	1.7	14.1%					
Asia	12.8	14.8	2.0	15.6%	14.0	7.5	-1.1%	15.5	4.6%
Exports to third parties	6.2	6.5	0.3	4.9%	5.9	2.6	-3.8%	5.1	-21.1%
Harnal	113.9	66.5	-47.3	-41.6%	64.6	30.8	-7.9%	61.7	-7.3%
Sales by Astellas	68.2	61.2	-6.9	-10.2%	60.4	28.9	-6.3%	57.8	-5.6%
Japan	35.0	29.6	-5.3	-15.3%	29.8	13.5	-9.3%	27.1	-8.7%
Europe	24.3	21.5	-2.7	-11.4%	20.7	9.9	-9.7%	19.6	-9.0%
Capsule	8.1	7.6	-0.5	-6.3%	7.0	3.1	-15.6%	6.7	-11.8%
Omnicon OCAS	16.2	13.9	-2.2	-13.9%	13.6	6.8	-6.7%	12.9	-7.5%
Asia	8.6	9.2	0.6	7.6%	9.2	5.0	10.3%	10.3	12.0%
Bulk and Royalties	45.6	5.2	-40.3	-88.5%	4.1	1.9	-26.9%	3.8	-26.6%
Vesicare	82.3	86.7	4.3	5.3%	89.5	46.1	10.6%	96.3	11.2%
Japan	22.9	25.5	2.5	11.2%	26.0	13.2	9.8%	27.2	6.5%
Americas	35.1	35.8	0.7	2.0%	38.2	18.9	6.3%	39.3	9.6%
Europe	22.9	23.5	0.5	2.5%	23.8	12.8	15.5%	27.1	15.0%
Asia	1.0	1.4	0.3	32.4%	1.4	1.1	74.2%	2.5	77.3%
Funguard/Mycamine	21.6	25.1	3.4	16.1%	24.4	13.3	8.6%	27.4	9.3%
Japan	11.8	12.6	0.8	7.2%	12.2	6.2	-0.8%	12.4	-2.1%
Americas	7.5	8.4	0.8	11.0%	7.9	4.2	0.5%	8.5	1.5%
Europe	1.2	2.4	1.1	95.3%	2.5	1.4	35.1%	3.4	42.4%
Asia	1.0	1.6	0.5	56.9%	1.8	1.4	99.4%	3.0	89.5%
Protopic	16.4	16.2	-0.1	-1.1%	17.4	8.6	6.8%	17.5	7.7%
Japan	2.8	2.9	0.0	2.7%	2.9	1.7	13.9%	3.4	15.3%
Americas	7.3	7.1	-0.1	-2.5%	8.0	3.3	-2.2%	6.8	-3.8%
Europe	5.5	5.2	-0.3	-5.7%	5.1	2.5	-0.2%	5.3	2.5%
Asia	0.7	0.9	0.2	31.2%	1.3	1.0	71.0%	1.9	95.7%

- Sales of products in Japan are shown in a gross sales basis.

2)Consolidated Sales of Other Products

billion yen

Rx Sales in Japan <Global products>	Mar 10 Full Year	Mar 11 Full Year	Change	Change (%)
Prograf (Including Graceptor)	33.8	39.6	5.8	17.3%
Harnal	35.0	29.6	-5.3	-15.3%
Vesicare	22.9	25.5	2.5	11.2%
Funguard	11.8	12.6	0.8	7.2%
Protopic	2.8	2.9	0.0	2.7%

<Domestic Products>

Lipitor	99.9	97.2	-2.6	-2.7%
Micardis	71.6	75.8	4.2	5.9%
Micombi	1.6	6.1	4.4	272.4%
Micamlo(Launched in October 2010)	-	2.3	2.3	-
Gaster	49.9	41.7	-8.2	-16.5%
Myslee	29.1	32.7	3.5	12.1%
Seroquel	23.6	26.4	2.8	12.0%
Vaccines	25.2	18.7	-6.5	-26.0%
Cefzon	10.6	9.4	-1.2	-11.5%
Frاندol	11.0	10.1	-0.9	-8.4%
Luvov	9.4	8.2	-1.2	-13.0%
Celecox	17.8	25.1	7.3	41.2%
Geninax	8.1	10.2	2.0	25.5%
Irribow	0.2	1.6	1.4	673.8%
Bonoteo	1.0	2.4	1.3	123.9%
Symbicort (Launched in January 2010)	1.5	11.9	10.4	689.0%
Total Rx Sales In Japan	509.8	525.6	15.8	3.1%

- Sales of products in Japan are shown in a gross sales basis.

billion yen

Mar 11 Revised
38.8
29.8
26.0
12.2
2.9

96.0
72.0
41.0
32.0
26.0
19.7
9.2
10.0
8.2
25.9
9.4
1.6
2.2
10.3
518.1

Forecasts

Mar 12 2Q	Change (%)	Mar 12 Full Year	Change (%)
21.6	12.5%	44.5	12.2%
13.5	-9.3%	27.1	-8.7%
13.2	9.8%	27.2	6.5%
6.2	-0.8%	12.4	-2.1%
1.7	13.9%	3.4	15.3%

Forecasts

49.2	2.4%	92.7	-4.7%
39.2	10.9%	81.4	7.3%
18.7	-11.3%	36.8	-11.8%
16.7	6.3%	34.2	4.6%
13.8	6.9%	27.9	5.3%
5.6	13.8%	19.7	5.2%
4.2	-11.8%	8.6	-8.7%
4.8	-6.0%	9.3	-8.0%
3.8	-12.2%	7.1	-13.6%
14.9	25.4%	30.9	22.8%
5.2	27.1%	12.0	17.6%
1.0	23.8%	2.0	19.0%
1.6	44.6%	5.1	109.1%
10.4	142.8%	24.3	102.6%
260.8	3.7%	533.0	1.4%

RX Sales in Americas and Europe		billion yen			
		Mar 10 Full Year	Mar 11 Full Year	Change	Change (%)
Scan*	(Americas)	46.0	47.9	1.9	4.2%
Lexiscan		30.2	39.0	8.7	28.9%
AmBisome	(Americas)	6.2	6.2	0.0	0.4%
Vaprisol	(Americas)	1.0	0.7	-0.2	-24.0%
Amevive	(Americas)	1.2	0.9	-0.3	-25.3%
VIBATIV	(Americas)	0.3	0.7	0.4	109.1%
Eligard	(Europe)	14.1	13.8	-0.2	-1.8%

* Adenoscan + Lexiscan

billion yen
Mar 11 Revised
47.6
5.7
1.2
1.0
13.5

Forecasts		Forecasts	
Mar 12 2Q	Change (%)	Mar 12 Full Year	Change (%)
23.5	-1.6%	45.7	-4.6%
2.8	-10.1%	5.6	-9.9%
0.3	6.7%	0.8	3.9%
0.3	-29.7%	0.5	-36.0%
6.8	1.9%	14.1	2.2%

Export Sales		billion yen			
		Mar 10 Full Year	Mar 11 Full Year	Change	Change (%)
Cefzon	Overseas(Exports to third party)	1.1	1.6	0.5	48.8%
Cefspan	Overseas(Exports to third party)	6.3	6.0	-0.3	-5.6%

billion yen
Mar 11 Revised
1.2
6.3

Forecasts		Forecasts	
Mar 12 2Q	Change (%)	Mar 12 Full Year	Change (%)
0.4	-28.8%	1.0	-37.3%
2.6	-21.4%	5.0	-16.6%

OSI-related revenues		billion yen			
		Mar 10 Full Year	Mar 11 Full Year	Change	Change (%)
OSI-related revenues Total		-	31.8	31.8	-
Tarceva US		-	14.1	14.1	-
Ex-US		-	10.3	10.3	-
DPP4 Royalty		-	6.8	6.8	-

billion yen
Mar 11 Revised
31.0

Forecasts		Forecasts	
Mar 12 2Q	Change (%)	Mar 12 Full Year	Change (%)
21.1	93.7%	42.1	32.6%

Sales in Americas and Europe

Unit:M\$

Americas	Mar 10 Full Year	Mar 11 Full Year	Change	Change (%)
Net Sales	1,936	2,176	239	12.4%
Prograf	734	478	-255	-34.9%
Scan*	495	559	63	12.8%
Lexiscan	326	455	129	39.6%
AmBisome	67	73	5	8.8%
Protopic	78	83	4	5.6%
VESIcare	378	418	39	10.5%
Mycamine	81	98	16	20.2%
Vaprisol	10	8	-1	-17.6%
Amevive	13	10	-2	-19.0%
VIBATIV	4	9	5	126.4%
Tarceva	-	285	285	-
US	-	165	165	-
ex-US	-	120	120	-
DPP4 Royalty	-	80	80	-

* Adenoscan + Lexiscan

Unit:M\$

Mar 11 Revised
2,242
465
563
67
95
452
93
15
12

Forecasts

Mar 12 2Q	Change (%)	Mar 12 Full Year	Change (%)
1,208	21.3%	2,408	10.7%
222	-6.9%	429	-10.1%
294	9.4%	571	2.2%
35	-0.1%	70	-3.5%
41	8.7%	85	3.1%
236	18.2%	491	17.5%
52	11.8%	106	8.7%
4	18.7%	10	11.3%
3	-21.9%	7	-31.4%

Unit:ME

Europe	Mar 10 Full Year	Mar 11 Full Year	Change	Change (%)
Net Sales	1,798	1,678	-119	-6.7%
Harnal	533	237	-296	-55.5%
Sales by Astellas	185	190	5	2.7%
Capsule	61	67	5	8.6%
OCAS	123	123	-0	-0.2%
Bulk and Royalties	348	46	-301	-86.6%
Prograf	545	592	46	8.4%
Sales by Astellas	501	535	34	6.9%
Advagraf	92	122	29	32.3%
Exports to third parties	44	56	11	25.4%
Vesicare	175	208	33	18.9%
Protopic	42	46	3	9.3%
Mycamine	9	21	11	126.4%
Eligard	107	122	14	13.9%
Qutenza	-	1	1	-

Unit:ME

Mar 11 Revised
1,638
222
185
63
122
37
557
506
51
213
46
23
121

Forecasts

Mar 12 2Q	Change (%)	Mar 12 Full Year	Change (%)
850	2.2%	1,739	3.6%
108	-10.0%	213	-10.0%
90	-6.6%	178	-6.5%
28	-12.6%	61	-9.3%
61	-3.5%	117	-4.9%
17	-24.3%	35	-24.6%
286	-2.7%	554	-6.3%
262	-2.9%	509	-5.0%
23	0.2%	45	-19.2%
116	19.5%	246	18.3%
23	3.3%	48	5.4%
13	39.8%	31	46.5%
62	5.5%	129	5.1%

11.Consolidated Balance Sheets

rounddown under 0.1 billion yen

Billion yen

	31-Mar-11	31-Mar-10	Change	Comments
	Amount	Amount		
Assets	1,335.0	1,364.1	-29.0	
Current assets	653.1	988.5	-335.3	
Cash on hand and in banks	142.8	312.1	-169.3	-360.4 Expenditures due to the acquisition of OSI and others
Trade notes and accounts receivable	262.5	228.0	34.4	
Marketable securities	33.9	225.0	-191.1	
Merchandise and finished goods	82.6	82.7	-0.0	
Work in process	13.6	12.1	1.4	
Raw materials and supplies	20.6	16.1	4.4	
Deferred tax assets	67.8	63.3	4.4	
Other	30.5	50.4	-19.9	
Allowance for doubtful receivables	-1.3	-1.6	0.2	
Fixed assets	681.9	375.6	306.3	
Property, plant and equipment	190.1	184.4	5.6	
Buildings and structures	97.1	96.1	0.9	
Machinery, equipment and vehicles	24.6	22.3	2.3	
Tools, furniture and fixtures	11.4	15.8	-4.3	
Land	31.3	30.1	1.1	
Construction in progress	24.1	18.6	5.4	
Other	1.4	1.3	0.1	
Intangible fixed assets	367.1	62.7	304.4	
Goodwill	101.2	22.1	79.0	Increase due to the acquisition of OSI
Patents	236.7	-	236.7	Increase due to the acquisition of OSI
Other	29.1	40.6	-11.4	
Investments and other assets	124.5	128.3	-3.7	
Investment securities	60.2	70.7	-10.5	
Deferred tax assets	52.2	46.8	5.3	
Other	12.1	10.7	1.4	
Allowance for doubtful receivables	-0.0	-0.0	0.0	

Billion yen

	31-Mar-11	31-Mar-10	Change	Comments
	Amount	Amount		
Liabilities and Net assets	1,335.0	1,364.1	-29.0	
Liabilities	313.9	310.2	3.7	
Current liabilities	239.6	277.1	-37.5	
Trade notes and accounts payable	88.6	84.0	4.5	
Other accounts payable	50.6	93.9	-43.3	
Accrued expenses	73.0	62.3	10.7	
Accrued income taxes	19.8	21.2	-1.4	
Accrued consumption tax	1.4	2.5	-1.1	
Deferred tax liabilities	-	0.0	-0.0	
Accrued bonus for directors	0.0	0.0	-0.0	
Provision	3.4	3.6	-0.2	
Other	2.6	9.3	-6.6	
Long-term liabilities	74.3	33.0	41.2	
Deferred tax liabilities	42.2	-	42.2	Deferred tax liabilities of OSI
Accrued retirement benefits for employees	17.2	17.6	-0.4	
Other provision	-	0.0	-0.0	
Other	14.8	15.4	-0.5	
Net assets	1,021.0	1,053.9	-32.8	
Common stock	103.0	103.0	-	
Capital surplus	176.8	176.8	-	
Retained earnings	874.3	895.1	-20.7	
Treasury stock	-23.4	-54.1	30.6	-Treasury Stock
Unrealized holding gains on securities	9.4	14.1	-4.6	Cancellation of treasury stock (+30.6)
Translation adjustments	-120.5	-82.5	-38.0	
Stock subscription rights	1.5	1.2	0.3	
Minority interests	-	0.3	-0.3	